Safety and Efficacy in Adult Subjects With Acute Migraines
BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Sponsor: Pfizer
Listed as NCT03237845, this PHASE3 trial focuses on Migraine, With or Without Aura and remains completed. Sponsored by Pfizer, it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Completed PHASE3
-
Feb 2021 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 11 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2019 — Sep 2019 [monthly]
Completed PHASE3
-
Feb 2019 — Jul 2019 [monthly]
Completed PHASE3
-
Sep 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .